Acumen Pharmaceuticals said it will present new research on its Alzheimer’s treatment candidate at the International Conference on Alzheimer’s and Parkinson’s Diseases 2026 in Copenhagen. The company ...

During Black History Month, a time meant to recognize both achievement and ongoing inequity, I had an experience that was not celebratory, but sobering. In a court proceeding tied to a commercial ...

Voters thought President Donald Trump’s supposed business acumen would improve the economic wellbeing of rich and poor alike. But his impact shows otherwise. These are just a few examples of poor ...

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Acumen Pharmaceuticals (ABOS) recently dosed the first ...

Acumen Pharmaceuticals recently reported that it has dosed the first participant in the open-label extension of its Phase 2 ALTITUDE-AD trial for Alzheimer’s candidate sabirnetug, while its Chief ...

Once, every middle-class home had a piano and a dictionary. The purpose of the piano was to be able to listen to music before phonographs were available and affordable. Later on, it was to torture ...

Here's some news for the word nerds out there. Merriam-Webster, the country’s oldest dictionary publisher, is releasing a hefty, new Collegiate edition for the first time in 22 years. “So, the ...

Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain Delivery TM product candidate in early 2026 Expect to report topline results for ALTITUDE-AD, a Phase 2 study to ...

Acumen Pharmaceuticals (NASDAQ:ABOS) is set to give its latest quarterly earnings report on Wednesday, 2025-11-12. Here's what investors need to know before the announcement. Analysts estimate that ...

One former Pfizer building is undergoing a monumental residential conversion courtesy of Nathan Berman and David Werner, the largest office-to-resi conversion in New York City. Another is celebrating ...

Management reaffirmed expectations for top line results from ALTITUDE-AD in late 2026, inclusive of key efficacy and safety measures. O'Connell stated, "We expect to make a development decision for up ...